CER Daily Newsfeed

Comparative Effectiveness of Diabetes Medications Revealed

(1/22, Bioengineer.org) reports “...Among the key findings, the study reveals significant variations in treatment effectiveness across different medications. For instance, some agents were found to lead to more substantial improvements in glycemic control compared to others, indicating a need for personalized medicine in diabetes care. Additionally, the implications of these findings extend beyond just clinical outcomes; they also touch upon quality of life measures which are critical considerations for patients managing chronic conditions.” Full

SGLT2 Inhibitors Linked to Lower Risk of CKD, AKI Than GLP-1 RAs

(1/21, Pearl Steinzor, The American Journal of Managed Care) reports “...‘Notably, the differences in kidney outcomes were consistent across subgroups and most pronounced among individuals without preexisting kidney disease, which underscores a potential for primary prevention,’ wrote the researchers. ‘Importantly, the divergent outcomes of eGFR [estimated glomerular filtration rate] and albuminuria suggest that combined treatment may offer additive benefits, which should be explored in future studies.’” Full

Comparing COPD Treatments: FF/1 UMEC/VI vs. BUD/GLY/FORM

(1/22, Bioengineer.org) reports “...A pivotal study by Wedzicha et al. has sparked a response that delves into the comparative effectiveness of different treatment combinations for patients transitioning from dual therapy to more advanced pharmacological interventions. This discourse not only highlights the evolving landscape of COPD management but also underscores the pressing need for continued research in this domain.” Full